- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00775099
Combustion Derived Air Pollution and Vascular Function
The Effects of Combustion-Derived Air Pollution on Vascular Vasomotor and Fibrinolytic Function in Healthy Volunteers (Diesel Exposure)
Air pollution is a major cause of cardiovascular morbidity and mortality. The components of air pollution responsible and the mechanisms through which they might mediate these harmful effects remain only partially understood. The link between cardiovascular disease and air pollution is strongest for fine particulate matter. Fine particulate matter (PM) is produced from the combustion of fossil fuels with the most significant threat thought to be posed by small particles less than 10µm (PM 10) which can be inhaled into the lungs. We propose to identify the precise component of diesel exhaust that mediates the adverse cardiovascular effects using a carbon particle generator, and a particle concentrator. The aim of this study proposal is to assess the vascular effects of different types and components of air pollution in healthy subjects. We intend to test the hypotheses that:
- Combustion derived nanoparticulate causes an acute impairment of endothelial vasomotor and fibrinolytic function in healthy volunteers.
- Exposure to combustion derived air pollution is associated with increased thrombus formation.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Edinburgh, Regno Unito, EH16 4SB
- University of Edinburgh
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy volunteers
Exclusion Criteria:
- Current smokers
- Significant occupational exposure to air pollution
- History of lung disease
- Women of child-bearing potential
- Malignant arrhythmias
- Renal or hepatic failure
- Significant co-morbidity
- Systolic blood pressure >190 or <100 mmHg
- Previous history of blood dyscrasia
- Unable to tolerate the supine position
- Lack of informed consent
- Blood donation within last 3 months
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Filtered Air Exposure
1 hour exposure to filtered air during intermittent exercise
|
Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
Altri nomi:
Ex-vivo assessment of thrombus formation using Badimon Chamber
|
Sperimentale: Diesel Exhaust Exposure
1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 during intermittent exercise
|
Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
Altri nomi:
Ex-vivo assessment of thrombus formation using Badimon Chamber
|
Sperimentale: Filtered Diesel Exposure
1 hour exposure to diesel exhaust with all particulates filtered out using teflon filter with intermittent exercise
|
Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
Altri nomi:
Ex-vivo assessment of thrombus formation using Badimon Chamber
|
Sperimentale: PALAS Exposure
1 hour exposure to pure carbon particles produced by PALAS generator during intermittent exercise
|
Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
Altri nomi:
Ex-vivo assessment of thrombus formation using Badimon Chamber
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Forearm blood flow measured by forearm venous occlusion plethysmography in response to infused vasodilators
Lasso di tempo: 6-8 hours after exposure
|
6-8 hours after exposure
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Ex-vivo thrombus formation assessed using the Badimon chamber
Lasso di tempo: 6 hours after exposure
|
6 hours after exposure
|
Arterial stiffness measured by radial artery tonometry
Lasso di tempo: Before and after exposure
|
Before and after exposure
|
Heart rate and heart rate variability measured with 3 lead Holter electrographic monitors
Lasso di tempo: During and for 24 hours after exposure
|
During and for 24 hours after exposure
|
Blood pressure
Lasso di tempo: During and after exposure and during forearm study
|
During and after exposure and during forearm study
|
Plasma t-PA and PAI concentrations following infusion of bradykinin
Lasso di tempo: During forearm study
|
During forearm study
|
Plasma inflammatory markers IL-6, TNF-alpha, IL-1 and hsCRP
Lasso di tempo: Before and after exposure
|
Before and after exposure
|
Platelet monocyte binding as measured by flow cytometry
Lasso di tempo: After the exposure
|
After the exposure
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Nicholas L Mills, MB BCh MRCP, University of Edinburgh
Pubblicazioni e link utili
Pubblicazioni generali
- Mills NL, Tornqvist H, Robinson SD, Gonzalez M, Darnley K, MacNee W, Boon NA, Donaldson K, Blomberg A, Sandstrom T, Newby DE. Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation. 2005 Dec 20;112(25):3930-6. doi: 10.1161/CIRCULATIONAHA.105.588962.
- Langrish JP, Watts SJ, Hunter AJ, Shah AS, Bosson JA, Unosson J, Barath S, Lundback M, Cassee FR, Donaldson K, Sandstrom T, Blomberg A, Newby DE, Mills NL. Controlled exposures to air pollutants and risk of cardiac arrhythmia. Environ Health Perspect. 2014 Jul;122(7):747-53. doi: 10.1289/ehp.1307337. Epub 2014 Mar 25.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 05/S1103/46
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Forearm Vascular Study
-
Digisight Technologies, Inc.SconosciutoRetinopatia diabetica | Degenerazione maculare legata all'età | MetamorfopsiaStati Uniti
-
University of MichiganCompletato
-
University of MichiganCompletatoTelemedicinaStati Uniti
-
St. Joseph's Healthcare HamiltonSospeso
-
AstraZenecaCompletatoCancro al seno | Oncologia | EpidemiologiaAlgeria
-
Deutsches Herzzentrum MuenchenCompletatoStenosi della valvola aorticaGermania
-
Cardiva Medical, Inc.CompletatoFerita chirurgicaStati Uniti
-
University of MichiganAttivo, non reclutanteDepressione | Attività fisica | Sonno | Stato d'animoStati Uniti
-
International Society for Vascular HealthCompletato
-
Fonds de la Recherche en Santé du QuébecUniversité de MontréalCompletatoIpertensione | Diabete mellito, tipo 2 | Dislipidemie | Colesterolo, LDL | ComorbiditàCanada